VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CNTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksCNTXInstitutional Holders

CNTX logoContext Therapeutics Inc. (CNTX) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership decreased this quarter (-12.44 pp), while top 10 holders maintain a highly concentrated 79.6% of value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
68.4%$34M total value · ▼ 12.44 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
51 / 100Neutral
Institutions & Flow79 holders+21 net flow (+35 / -14)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+21)
  • Renaissance Technologies Llc and Jane Street Group, Llc maintain significant positions
  • Top 10 holders control 79.6% of institutional value
  • No Insider Signal

Top Institutional Holders of CNTX

Ranked by reported Q2 2026 13F market value

Top 10 Holders
79.6%
Top 25 Holders
96.2%

Share of total reported institutional value in CNTX held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1Nextech Invest Ltd.7.4M$4.1M0.0%8.075%0.20%
2Deep Track Capital, LP7.4M$4.1M0.0%8.075%0.06%
3Soleus Capital Management, L.P.7.1M$3.9M+1.4%7.687%0.13%

Quarterly Institutional Activity

Filings activity in CNTX during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers35Added To8Trimmed35Exited14
  • Nextech Invest Ltd.$4.1M
  • Deep Track Capital, LP$4.1M
  • Soleus Capital Management, L.P.

CNTX Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 202679+32%68.36%12.44 pp$34M82%
Q1 202660+43%80.80%+9.84 pp$194M+103%
Q4 202542+14%70.96%4.10 pp$96M+43%
Q3 2025377.5%75.06%1.43 pp$67M+49%
Q2 2025409.1%76.49%3.11 pp$45M+2.9%
Q1 20254417%

How CNTX Compares to Peers

Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
DMRADamora Therapeutics, Inc.$1.46B200.0%99+33
FTHFaeth Therapeutics, Inc.$568M54.5%45+16
LONALeonaBio, Inc.$17M184.4%45+4
KYNBKyntra Bio, Inc.$15M26.9%29-4
CNSYCerenome, Inc.$5M4.8%24-5

CNTX — Frequently Asked Questions

Quick answers to the most common questions about buying CNTX stock.

What percentage of CNTX is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Context Therapeutics Inc. stands at 68.4%, held across 79 reporting institutions.

Who is the largest institutional holder of CNTX?

Nextech Invest Ltd. is the largest reported institutional holder of CNTX, with approximately 7,419,355 shares worth $0.00B as of Q2 2026.

Is CNTX a hedge fund favorite?

Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of CNTX, including RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC.

What is CNTX's Smart Money Score?

Our composite Smart Money Score for CNTX is 51 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought CNTX this quarter?
4BlackRock, Inc.6.2M$3.4M+628.6%6.714%0.00%
5Avidity Partners Management LP5.0M$2.8M0.0%5.440%0.44%
6FRANKLIN TEMPLETON INC3.8M$2.1M0.0%4.139%0.00%
7VANGUARD CAPITAL MANAGEMENT LLC3.4M$1.9M0.0%3.735%0.00%
8Octagon Capital Advisors LP3.0M$1.7M-41.9%3.320%0.15%
9Blue Owl Capital Holdings LP2.9M$1.6M-42.4%3.193%0.24%
10TCG Crossover Management, LLC2.7M$1.5M0.0%2.920%0.04%
11GEODE CAPITAL MANAGEMENT, LLC1.8M$1.0M+203.1%1.992%0.00%
12STATE STREET CORP1.4M$783K+505.3%1.538%0.00%
13MPM BioImpact LLC1.3M$720K-87.8%1.414%0.04%
14RENAISSANCE TECHNOLOGIES LLC1.0M$577K+469.1%1.133%0.00%
15ADAR1 Capital Management, LLC751K$416K+113.9%0.817%0.02%
16JANE STREET GROUP, LLC645K$357K+47.7%0.702%0.00%
17VANGUARD PORTFOLIO MANAGEMENT LLC639K$354K—0.695%0.00%
18NORTHERN TRUST CORP616K$341K+496.2%0.670%0.00%
19VANGUARD FIDUCIARY TRUST CO434K$240K+27.1%0.472%0.00%
20MARSHALL WACE, LLP385K$211K-87.0%0.419%0.00%
21XTX Topco Ltd294K$163K—0.320%0.00%
22Qube Research & Technologies Ltd257K$142K+2155.4%0.280%0.00%
23CHARLES SCHWAB INVESTMENT MANAGEMENT INC228K$126K—0.248%0.00%
24Pathstone Holdings, LLC215K$119K+94.9%0.234%0.00%
25Timothy G. Youngquist 2020 Irrevocable Trust198K$110K—0.216%0.01%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in CNTX — a direct measure of their conviction.

$3.9M
  • Avidity Partners Management LP$2.8M
  • FRANKLIN TEMPLETON INC$2.1M
  • VANGUARD CAPITAL MANAGEMENT LLC$1.9M
  • Octagon Capital Advisors LP$1.7M
  • Blue Owl Capital Holdings LP$1.6M
  • TCG Crossover Management, LLC$1.5M
  • GEODE CAPITAL MANAGEMENT, LLC$1.0M
  • MPM BioImpact LLC$720K
  • ADAR1 Capital Management, LLC$416K
  • 79.60%
    1.54 pp
    $44M
    43%
    Q4 202453+23%81.14%+5.56 pp$76M31%
    Q3 202443—75.58%—$111M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    35 institutions opened new positions in CNTX during Q2 2026, while 14 fully exited. 8 added to existing positions and 35 trimmed.

    How is institutional ownership of CNTX changing?

    CNTX institutional ownership fell by 12.44 percentage points quarter-over-quarter, with a net change of +19 holders.

    How concentrated is CNTX ownership among the top holders?

    The top 10 institutions account for 79.6% of all reported 13F value in CNTX, and the top 25 account for 96.2%.

    How does CNTX compare to Oncology Biotech on institutional ownership?

    Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.

    Where does this CNTX institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    CNTXContext Therapeutics Inc.
    $0.17$15M
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership